In addition to these endogenous promoters, we also utilized a modified version of the canine adenoviral E1A promoter, containing four E2F binding sites and one Sp-I site (E2F enhanced E1A promoter, or EEE), which has previously been shown to be upregulated in activity in tumor cells [44]. The gene discussed is DHTKD1; the disease is neoplasm.